Authors
Lameck Marcel, Faryal M Raza, Faustini C Kimondo, Simon C Peter, Abid M Sadiq
Published in
International journal of immunopathology and pharmacology. Volume 40. Pages 3946320261502342. Epub Oct 26, 2026.
Abstract
BackgroundInflammation contributes to heart failure (HF) progression, and readily available inflammatory biomarkers may provide prognostic information. We evaluated the association and discriminatory performance of admission neutrophil-to-lymphocyte ratio (NLR) and neutrophil-and-monocyte-to-lymphocyte ratio (NMLR) for in-hospital mortality in acute HF.MethodsThis secondary analysis of a cross-sectional study included consecutive patients aged ≥14 years admitted with acute HF to Kilimanjaro Christian Medical Centre, Tanzania, between 1 May and 31 October 2024. Admission NLR and NMLR were calculated from routine hematological parameters and natural log-transformed for logistic regression because of skewed distributions. Univariable and multivariable binary logistic regression assessed associations with in-hospital mortality; variables with p<0.10 in univariable analysis were considered for multivariable inclusion. Receiver operating characteristic (ROC) analysis assessed discrimination and identified study-specific thresholds.ResultsAmong 290 patients, 228 (78.6%) were discharged and 62 (21.4%) died. Higher LN(NLR) was associated with mortality in univariable analysis (cOR: 1.47; 95% CI: 1.11-1.96; p=0.008) and remained independently associated after adjustment (aOR: 1.45; 95% CI: 1.04-2.01; p=0.028). Similarly, LN(NMLR) was associated with mortality (cOR: 1.47; 95% CI: 1.10-1.97; p=0.009) and remained independently associated after adjustment (aOR: 1.44; 95% CI: 1.03-2.02; p=0.032). NLR and NMLR demonstrated modest discrimination, with AUCs of 0.625 (95% CI: 0.544-0.705) and 0.624 (95% CI: 0.543-0.705), respectively. Thresholds were 5.35 for NLR and 6.47 for NMLR.ConclusionHigher admission NLR and NMLR were independently associated with in-hospital mortality and demonstrated modest discriminatory ability. These inexpensive biomarkers may complement clinical risk stratification, although the thresholds require external validation.
PMID:
42929770
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0